LeMaitre Vascular (LMAT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
The annual meeting is scheduled for June 2, 2026, with voting on director elections, executive compensation, and auditor ratification.
Proxy materials are distributed primarily online to reduce environmental impact and costs.
Shareholders can vote online, by phone, or by mail, and may attend the meeting in person with proper identification.
Voting matters and shareholder proposals
Shareholders will vote to elect two Class II directors for three-year terms, approve a non-binding advisory vote on 2025 executive compensation, and ratify Grant Thornton LLP as the independent auditor for 2026.
The board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be received by December 18, 2026, with specific advance notice requirements.
Board of directors and corporate governance
The board will be reduced to seven members after the meeting, with a staggered three-class structure.
Five directors are deemed independent under Nasdaq standards.
The board is chaired by the CEO, with no lead independent director.
Committees include Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
The board has adopted a Code of Business Conduct and Ethics, Corporate Governance Guidelines, and a Director Resignation Policy.
Latest events from LeMaitre Vascular
- Q2 2026 saw double-digit sales and EPS growth, with strong margins and global expansion.LMAT
Q2 2026 - Q1 2026 saw 11% sales and 42% EPS growth, with raised guidance and strong biologics momentum.LMAT
Q1 2026 - Votes will be held on director elections, executive pay, and auditor ratification at the June 2026 meeting.LMAT
Proxy filing - Double-digit growth, global expansion, and 15 years of dividend increases drive strong outlook.LMAT
Investor presentation - Q4 2025 saw 16% sales and 47% profit growth; 2026 outlook features strong growth and capital returns.LMAT
Q4 2025 - Q3 2024 sales up 16%, EPS up 49%, with raised guidance and strong biologics-driven growth.LMAT
Q3 2024 - Q2 net income up 46% on 11% sales growth; 2024 guidance raised for sales and EPS.LMAT
Q2 2024 - Q1 2025 saw 13% organic sales growth, margin gains, and a raised outlook amid global expansion.LMAT
Q1 2025 - Double-digit growth, margin gains, and higher shareholder returns drive 2025 outlook.LMAT
Q4 2024